Selective Identification of Hedgehog Pathway Antagonists by Direct Analysis of Smoothened Ciliary Translocation

DSpace/Manakin Repository

Selective Identification of Hedgehog Pathway Antagonists by Direct Analysis of Smoothened Ciliary Translocation

Citable link to this page

. . . . . .

Title: Selective Identification of Hedgehog Pathway Antagonists by Direct Analysis of Smoothened Ciliary Translocation
Author: Wang, Yu; Davidow, Lance Steven; Blanchard, Joel; Lam, Kelvin; Yoo, Jin Woo; Coy, Shannon; McMahon, Andrew P.; Rubin, Lee L.; Arvanites, Anthony C.

Note: Order does not necessarily reflect citation order of authors.

Citation: Wang, Yu, Anthony C. Arvanites, Lance Steven Davidow, Joel Blanchard, Kelvin Lam, Jin Woo Yoo, Shannon Coy, Lee L. Rubin, and Andrew P. McMahon. 2012. Selective identification of hedgehog pathway antagonists by direct analysis of smoothened ciliary translocation. ACS Chemical Biology 7(6): 1040–1048.
Full Text & Related Files:
Abstract: Hedgehog (Hh) signaling promotes tumorigenesis. The accumulation of the membrane protein Smoothened (Smo) within the primary cilium (PC) is a key event in Hh signal transduction, and many pharmacological inhibitors identified to date target Smo’s actions. Smo ciliary translocation is inhibited by some pathway antagonists, while others promote ciliary accumulation, an outcome that can lead to a hypersensitive state on renewal of Hh signaling. To identify novel inhibitory compounds acting on the critical mechanistic transition of Smo accumulation, we established a high content screen to directly analyze Smo ciliary translocation. Screening thousands of compounds from annotated libraries of approved drugs and other agents, we identified several new classes of compounds that block Sonic hedgehog-driven Smo localization within the PC. Selective analysis was conducted on two classes of Smo antagonists. One of these, DY131, appears to inhibit Smo signaling through a common binding site shared by previously reported Smo agonists and antagonists. Antagonism by this class of compound is competed by high doses of Smo-binding agonists such as SAG and impaired by a mutation that generates a ligand-independent, oncogenic form of Smo (SmoM2). In contrast, a second antagonist of Smo accumulation within the PC, SMANT, was less sensitive to SAG-mediated competition and inhibited SmoM2 at concentrations similar to those that inhibit wild-type Smo. Our observations identify important differences among Hh antagonists and the potential for development of novel therapeutic approaches against mutant forms of Smo that are resistant to current therapeutic strategies.
Published Version: doi:10.1021/cb300028a
Other Sources: http://www.ncbi.nlm.nih.gov/pubmed/22554036
Terms of Use: This article is made available under the terms and conditions applicable to Open Access Policy Articles, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#OAP
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:8730547

Show full Dublin Core record

This item appears in the following Collection(s)

  • FAS Scholarly Articles [6902]
    Peer reviewed scholarly articles from the Faculty of Arts and Sciences of Harvard University
 
 

Search DASH


Advanced Search
 
 

Submitters